{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:50:21Z","timestamp":1791478221859,"version":"4.3.4"},"reference-count":91,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2018,2,25]],"date-time":"2018-02-25T00:00:00Z","timestamp":1519516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1GM118973"],"award-info":[{"award-number":["UL1GM118973"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Neisseria meningitidis causes most cases of bacterial meningitis. Meningococcal meningitis is a public health burden to both developed and developing countries throughout the world. There are a number of vaccines (polysaccharide-based, glycoconjugate, protein-based and combined conjugate vaccines) that are approved to target five of the six disease-causing serogroups of the pathogen. Immunization strategies have been effective at helping to decrease the global incidence of meningococcal meningitis. Researchers continue to enhance these efforts through discovery of new antigen targets that may lead to a broadly protective vaccine and development of new methods of homogenous vaccine production. This review describes current meningococcal vaccines and discusses some recent research discoveries that may transform vaccine development against N. meningitidis in the future.<\/jats:p>","DOI":"10.3390\/vaccines6010012","type":"journal-article","created":{"date-parts":[[2018,2,27]],"date-time":"2018-02-27T03:36:12Z","timestamp":1519702572000},"page":"12","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":56,"title":["Meningococcal Vaccines: Current Status and Emerging Strategies"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4096-1677","authenticated-orcid":false,"given":"Pumtiwitt C.","family":"McCarthy","sequence":"first","affiliation":[{"name":"Department of Chemistry, Morgan State University, Baltimore, MD 21251, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abeer","family":"Sharyan","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Morgan State University, Baltimore, MD 21251, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laleh","family":"Sheikhi Moghaddam","sequence":"additional","affiliation":[{"name":"Department of Chemistry, Morgan State University, Baltimore, MD 21251, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2018,2,25]]},"reference":[{"key":"ref_1","unstructured":"World Health Organization (2018, January 19). Meningococcal Meningitis Fact Sheet. Available online: http:\/\/www.who.int\/mediacentre\/factsheets\/fs141\/en\/."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"170","DOI":"10.4161\/hv.7.2.13717","article-title":"Meningococcal glycoconjugate vaccines","volume":"7","author":"Gasparini","year":"2011","journal-title":"Hum. Vaccin."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1574-6976.2006.00051.x","article-title":"Conquering the meningococcus","volume":"31","author":"Stephens","year":"2007","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1080\/14760584.2017.1258308","article-title":"The Global Meningococcal Initiative: Global epidemiology, the impact of vaccines on meningococcal disease and the importance of herd protection","volume":"16","author":"Borrow","year":"2017","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_5","first-page":"85","article-title":"Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: A new conjugate vaccine against invasive meningococcal disease","volume":"7","author":"Hedari","year":"2014","journal-title":"Infect. Drug Resist."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Feavers, I.M., and Maiden, M.C.J. (2017). Recent Progress in the Prevention of Serogroup B Meningococcal Disease. Clin. Vaccine Immunol., 24.","DOI":"10.1128\/CVI.00566-16"},{"key":"ref_7","unstructured":"World Health Organization (2018, January 19). Meningococcal Meninigitis: Emergency preparedness and response. Available online: http:\/\/www.who.int\/csr\/disease\/meningococcal\/en\/."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/eji.1830010104","article-title":"The carrier effect in the secondary response to hapten-protein conjugates. II. Cellular cooperation","volume":"1","author":"Mitchison","year":"1971","journal-title":"Eur. J. Immunol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2874-3_1","article-title":"Carbohydrate-Based Vaccines: An Overview","volume":"1331","author":"Hutter","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/j.vaccine.2008.01.022","article-title":"Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases","volume":"26","author":"Bardotti","year":"2008","journal-title":"Vaccine"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.4161\/hv.26109","article-title":"Protein carriers of conjugate vaccines: Characteristics, development, and clinical trials","volume":"9","author":"Pichichero","year":"2013","journal-title":"Hum. Vaccin. Immunother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4","DOI":"10.4103\/0022-3859.173187","article-title":"The clinical development process for a novel preventive vaccine: An overview","volume":"62","author":"Singh","year":"2016","journal-title":"J. Postgrad. Med."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"LaForce, F.M., Djingarey, M., Viviani, S., and Preziosi, M.P. (2017). Lessons from the Meningitis Vaccine Project. Viral. Immunol.","DOI":"10.1089\/vim.2017.0120"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1093\/cid\/civ595","article-title":"Technical Development of a New Meningococcal Conjugate Vaccine","volume":"61","author":"Frasch","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1586\/erv.12.32","article-title":"MenACWY-TT vaccine for active immunization against invasive meningococcal disease","volume":"11","author":"Papaevangelou","year":"2012","journal-title":"Expert. Rev. Vaccines"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.phrs.2014.10.006","article-title":"Immunogenicity of meningococcal quadrivalent (serogroup A, C, W135 and Y) tetanus toxoid conjugate vaccine: Systematic review and meta-analysis","volume":"92","author":"Pellegrino","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijid.2014.03.1390","article-title":"Immunogenicity and safety of a quadrivalent meningococcal polysaccharide CRM conjugate vaccine in infants and toddlers","volume":"26","author":"Tregnaghi","year":"2014","journal-title":"Int. J. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Miller, J.M., Mesaros, N., Van Der Wielen, M., and Baine, Y. (2011). Conjugate Meningococcal Vaccines Development: GSK Biologicals Experience. Adv. Prev. Med.","DOI":"10.4061\/2011\/846756"},{"key":"ref_19","unstructured":"(2018, January 30). World Health Organization: Immunization, Vaccines and Biologicals\u2014Haemophilus influenzae type b (Hib). Available online: http:\/\/www.who.int\/immunization\/topics\/hib\/en\/."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/iai.45.3.582-591.1984","article-title":"Serum antibody responses of juvenile and infant rhesus monkeys injected with Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-protein conjugates","volume":"45","author":"Schneerson","year":"1984","journal-title":"Infect. Immun."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"12695","DOI":"10.1016\/S0021-9258(17)38929-9","article-title":"CMP-NeuNAc:poly-alpha-2,8-sialosyl sialyltransferase and the biosynthesis of polysialosyl units in neural cell adhesion molecules","volume":"260","author":"McCoy","year":"1985","journal-title":"J. Biol. Chem."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/0882-4010(89)90087-9","article-title":"Protective efficacy of mouse serum to the N-propionyl derivative of meningococcal group B polysaccharide","volume":"6","author":"Ashton","year":"1989","journal-title":"Microb. Pathog."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1084\/jem.165.4.1207","article-title":"N-propionylated group B meningococcal polysaccharide mimics a unique epitope on group B Neisseria meningitidis","volume":"165","author":"Jennings","year":"1987","journal-title":"J. Exp. Med."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4049\/jimmunol.137.5.1708","article-title":"Induction of meningococcal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine","volume":"137","author":"Jennings","year":"1986","journal-title":"J. Immunol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00262-011-1083-6","article-title":"Immunization with N-propionyl polysialic acid-KLH conjugate in patients with small cell lung cancer is safe and induces IgM antibodies reactive with SCLC cells and bactericidal against group B meningococci","volume":"61","author":"Krug","year":"2012","journal-title":"Can. Immunol. Immunother."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.37757\/MR2007V9.N1.6","article-title":"Cuban Meningococcal BC Vaccine: Experiences & Contributions from 20 Years of Application","volume":"9","author":"Sotolongo","year":"2007","journal-title":"MEDICC Rev."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1126\/science.287.5459.1816","article-title":"Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing","volume":"287","author":"Pizza","year":"2000","journal-title":"Science"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1126\/science.287.5459.1809","article-title":"Complete genome sequence of Neisseria meningitidis serogroup B strain MC58","volume":"287","author":"Tettelin","year":"2000","journal-title":"Science"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.immuni.2010.09.017","article-title":"Reverse vaccinology: Developing vaccines in the era of genomics","volume":"33","author":"Sette","year":"2010","journal-title":"Immunity"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1021\/acs.accounts.7b00106","article-title":"Advancing Homogeneous Antimicrobial Glycoconjugate Vaccines","volume":"50","author":"Adamo","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"6468","DOI":"10.1016\/j.vaccine.2009.06.013","article-title":"Preparation of bacterial polysaccharide-protein conjugates: Analytical and manufacturing challenges","volume":"27","author":"Frasch","year":"2009","journal-title":"Vaccine"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"6673","DOI":"10.1039\/c2ob25222h","article-title":"Synthesis and preliminary biological evaluation of carba analogues from Neisseria meningitidis A capsular polysaccharide","volume":"10","author":"Gao","year":"2012","journal-title":"Org. Biomol. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","article-title":"Meningococcal surrogates of protection\u2014serum bactericidal antibody activity","volume":"23","author":"Borrow","year":"2005","journal-title":"Vaccine"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"9157","DOI":"10.1002\/anie.201302540","article-title":"Synthesis of Neisseria meningitidis serogroup W135 capsular oligosaccharides for immunogenicity comparison and vaccine development","volume":"52","author":"Wang","year":"2013","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1039\/C7QO00468K","article-title":"Synthesis and immunochemical evaluation of a novel Neisseria meningitidis serogroup A tetrasaccharide and its conjugate","volume":"4","author":"Harale","year":"2017","journal-title":"Org. Chem. Front."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9647","DOI":"10.1039\/C5CC01794G","article-title":"Synthesis and immunological study of alpha-2,9-oligosialic acid conjugates as anti-group C meningitis vaccines","volume":"51","author":"Liao","year":"2015","journal-title":"Chem. Commun. (Camb)"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1111\/j.1365-2958.2007.05862.x","article-title":"Biochemical characterization of a Neisseria meningitidis polysialyltransferase reveals novel functional motifs in bacterial sialyltransferases","volume":"65","author":"Freiberger","year":"2007","journal-title":"Mol. Microbiol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1128\/JB.00924-10","article-title":"Characterization and acceptor preference of a soluble meningococcal group C polysialyltransferase","volume":"193","author":"Peterson","year":"2011","journal-title":"J. Bacteriol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"11718","DOI":"10.1074\/jbc.M113.452276","article-title":"Biochemical and biophysical characterization of the sialyl-\/hexosyltransferase synthesizing the meningococcal serogroup W135 heteropolysaccharide capsule","volume":"288","author":"Romanow","year":"2013","journal-title":"J. Biol. Chem."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1093\/glycob\/cwt102","article-title":"Functional expression of the capsule polymerase of Neisseria meningitidis serogroup X: A new perspective for vaccine development","volume":"24","author":"Fiebig","year":"2014","journal-title":"Glycobiology"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"19395","DOI":"10.1074\/jbc.M114.575142","article-title":"Molecular cloning and functional characterization of components of the capsule biosynthesis complex of Neisseria meningitidis serogroup A: Toward in vitro vaccine production","volume":"289","author":"Fiebig","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/glycob\/cwt091","article-title":"Characterization of the meningococcal serogroup X capsule N-acetylglucosamine-1-phosphotransferase","volume":"24","author":"Muindi","year":"2014","journal-title":"Glycobiology"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"33945","DOI":"10.1074\/jbc.M114.597773","article-title":"Dissection of hexosyl- and sialyltransferase domains in the bifunctional capsule polymerases from Neisseria meningitidis W and Y defines a new sialyltransferase family","volume":"289","author":"Romanow","year":"2014","journal-title":"J. Biol. Chem."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1093\/glycob\/cwx100","article-title":"Interaction of Neisseria meningitidis Group X N-acetylglucosamine-1-phosphotransferase with its donor substrate","volume":"28","author":"Ming","year":"2018","journal-title":"Glycobiology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3109\/10242420903388694","article-title":"Chemoenzymatic synthesis of conjugatable oligosialic acids","volume":"28","author":"Mosley","year":"2010","journal-title":"Biocatal. Biotransformation."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10719-013-9490-x","article-title":"Chemoenzymatic synthesis of immunogenic meningococcal group C polysialic acid-tetanus Hc fragment glycoconjugates","volume":"30","author":"McCarthy","year":"2013","journal-title":"Glycoconj. J."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Fiebig, T., Romano, M.R., Oldrini, D., Adamo, R., Tontini, M., Brogioni, B., Santini, L., Berger, M., Costantino, P., and Berti, F. (2016). An efficient cell free enzyme-based total synthesis of a meningococcal vaccine candidate. NPJ Vaccines, 1.","DOI":"10.1038\/npjvaccines.2016.17"},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Fiebig, T., Litschko, C., Freiberger, F., Bethe, A., Berger, M., and Gerardy-Schahn, R. (2017). Efficient solid-phase synthesis of meningococcal capsular oligosaccharides enables simple and fast chemoenzymatic vaccine production. J. Biol. Chem.","DOI":"10.1074\/jbc.RA117.000488"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1093\/glycob\/cwv091","article-title":"Symbol Nomenclature for Graphical Representations of Glycans","volume":"25","author":"Varki","year":"2015","journal-title":"Glycobiology"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1016\/j.vaccine.2016.06.039","article-title":"Preclinical studies on new proteins as carrier for glycoconjugate vaccines","volume":"34","author":"Tontini","year":"2016","journal-title":"Vaccine"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10719-010-9287-0","article-title":"Investigating the candidacy of LPS-based glycoconjugates to prevent invasive meningococcal disease: Chemical strategies to prepare glycoconjugates with good carbohydrate loading","volume":"27","author":"Cox","year":"2010","journal-title":"Glycoconj. J."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.11.016","article-title":"Antigenic potential of a highly conserved Neisseria meningitidis lipopolysaccharide inner core structure defined by chemical synthesis","volume":"22","author":"Reinhardt","year":"2015","journal-title":"Chem. Biol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.biotechadv.2017.05.003","article-title":"Bioengineering bacterial outer membrane vesicles as vaccine platform","volume":"35","author":"Gerritzen","year":"2017","journal-title":"Biotechnol. Adv."},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Christodoulides, M., and Heckels, J. (2017). Novel approaches to Neisseria meningitidis vaccine design. Pathog. Dis.","DOI":"10.1093\/femspd\/ftx033"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e66536","DOI":"10.1371\/journal.pone.0066536","article-title":"Mutant Native Outer Membrane Vesicles Combined with a Serogroup A Polysaccharide Conjugate Vaccine for Prevention of Meningococcal Epidemics in Africa","volume":"8","author":"Pajon","year":"2013","journal-title":"PLoS ONE"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"4810","DOI":"10.1016\/j.vaccine.2010.04.082","article-title":"Improved OMV vaccine against Neisseria meningitidis using genetically engineered strains and a detergent-free purification process","volume":"28","author":"Streefland","year":"2010","journal-title":"Vaccine"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/j.1574-6976.2006.00057.x","article-title":"Molecular typing of meningococci: Recommendations for target choice and nomenclature","volume":"31","author":"Jolley","year":"2007","journal-title":"FEMS Microbiol. Rev."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"B18","DOI":"10.1016\/j.vaccine.2012.01.062","article-title":"Meningococcal vaccine development--from glycoconjugates against MenACWY to proteins against MenB\u2014potential for broad protection against meningococcal disease","volume":"30","author":"Dull","year":"2012","journal-title":"Vaccine"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1111\/mmi.13747","article-title":"Heterogeneity in non-epitope loop sequence and outer membrane protein complexes alters antibody binding to the major porin protein PorB in serogroup B Neisseria meningitidis","volume":"105","author":"Matthias","year":"2017","journal-title":"Mol. Microbiol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.1128\/IAI.05019-11","article-title":"The Neisseria meningitidis macrophage infectivity potentiator protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate","volume":"79","author":"Hung","year":"2011","journal-title":"Infect. Immun."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/IAI.01815-14","article-title":"Recombinant protein truncation strategy for inducing bactericidal antibodies to the macrophage infectivity potentiator protein of Neisseria meningitidis and circumventing potential cross-reactivity with human FK506-binding proteins","volume":"83","author":"Bielecka","year":"2015","journal-title":"Infect. Immun."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1111\/apm.12709","article-title":"Liposomes or traditional adjuvants: Induction of bactericidal activity by the macrophage infectivity potentiator protein (Mip) of Neisseria meningitidis","volume":"125","author":"Costoya","year":"2017","journal-title":"Apmis"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Hung, M.C., Heckels, J.E., and Christodoulides, M. (2013). The adhesin complex protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. MBio, 4.","DOI":"10.1128\/mBio.00041-13"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1016\/j.vaccine.2015.07.032","article-title":"A putative amino acid ABC transporter substrate-binding protein, NMB1612, from Neisseria meningitidis, induces murine bactericidal antibodies against meningococci expressing heterologous NMB1612 proteins","volume":"33","author":"Hung","year":"2015","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"8420","DOI":"10.1016\/j.vaccine.2007.09.053","article-title":"Lipoprotein NMB0928 from Neisseria meningitidis serogroup B as a novel vaccine candidate","volume":"25","author":"Delgado","year":"2007","journal-title":"Vaccine"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1099\/jmm.0.004820-0","article-title":"Neisseria meningitidis antigen NMB0088: Sequence variability, protein topology and vaccine potential","volume":"58","author":"Sardinas","year":"2009","journal-title":"J. Med. Microbiol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1128\/CVI.05683-11","article-title":"Improvement of immunogenicity of meningococcal lipooligosaccharide by coformulation with lipidated transferrin-binding protein B in liposomes: Implications for vaccine development","volume":"19","author":"Mistretta","year":"2012","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ijpharm.2012.12.046","article-title":"Study of the stability of proteoliposomes as vehicles for vaccines against Neisseria meningitidis based on recombinant porin complexes","volume":"443","author":"Freixeiro","year":"2013","journal-title":"Int. J. Pharm."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1099\/mic.0.000227","article-title":"Dissection of the function of the RmpM periplasmic protein from Neisseria meningitidis","volume":"162","author":"Maharjan","year":"2016","journal-title":"Microbiology"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1016\/j.vaccine.2013.03.033","article-title":"Immunization with recombinant Chaperonin60 (Chp60) outer membrane protein induces a bactericidal antibody response against Neisseria meningitidis","volume":"31","author":"Phillips","year":"2013","journal-title":"Vaccine"},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Gregory, A., Williamson, D., and Titball, R. (2013). Vaccine delivery using nanoparticles. Front. Cell. Infect. Microbiol.","DOI":"10.3389\/fcimb.2013.00013"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1128\/CVI.00423-09","article-title":"Coincorporation of LpxL1 and PagL mutant lipopolysaccharides into liposomes with Neisseria meningitidis opacity protein: Influence on endotoxic and adjuvant activity","volume":"17","author":"Arenas","year":"2010","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1016\/j.vaccine.2004.03.047","article-title":"Intranasal immunisation of mice with liposomes containing recombinant meningococcal OpaB and OpaJ proteins","volume":"22","author":"Hamstra","year":"2004","journal-title":"Vaccine"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1021\/pr3008573","article-title":"High resolution clear native electrophoresis (hrCNE) allows a detailed analysis of the heterotrimeric structure of recombinant Neisseria meningitidis porins inserted into liposomes","volume":"12","author":"Freixeiro","year":"2013","journal-title":"J. Proteome. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.1016\/j.vaccine.2009.06.086","article-title":"Characterisation and immune responses to meningococcal recombinant porin complexes incorporated into liposomes","volume":"27","author":"Sanchez","year":"2009","journal-title":"Vaccine"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"3042","DOI":"10.1073\/pnas.1524290113","article-title":"Type VI secretion system sheaths as nanoparticles for antigen display","volume":"113","author":"Danilchanka","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"3930","DOI":"10.1016\/j.vaccine.2017.06.018","article-title":"Optimizing adjuvants for intradermal delivery of MenC glycoconjugate vaccine","volume":"35","author":"Donadei","year":"2017","journal-title":"Vaccine"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Liang, F., and Lore, K. (2016). Local innate immune responses in the vaccine adjuvant-injected muscle. Clin. Transl. Immunol., 5.","DOI":"10.1038\/cti.2016.19"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1126\/science.1095209","article-title":"A Synthetic Conjugate Polysaccharide Vaccine Against Haemophilus influenzae Type b","volume":"305","author":"Hardy","year":"2004","journal-title":"Science."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1128\/CVI.00144-06","article-title":"Phase I Clinical Evaluation of a Synthetic Oligosaccharide-Protein Conjugate Vaccine against Haemophilus influenzae Type b in Human Adult Volunteers","volume":"13","author":"Toledo","year":"2006","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1128\/CVI.00009-07","article-title":"Protective meningococcal capsular polysaccharide epitopes and the role of O acetylation","volume":"14","author":"Fusco","year":"2007","journal-title":"Clin. Vaccine Immunol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1074\/jbc.M807518200","article-title":"The polysialic acid-specific O-acetyltransferase OatC from Neisseria meningitidis serogroup C evolved apart from other bacterial sialate O-acetyltransferases","volume":"284","author":"Bergfeld","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"42765","DOI":"10.1074\/jbc.M313552200","article-title":"The Neisseria meningitidis serogroup A capsular polysaccharide O-3 and O-4 acetyltransferase","volume":"279","author":"Gudlavalleti","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"24501","DOI":"10.1074\/jbc.M109.006049","article-title":"Structural and kinetic characterizations of the polysialic acid O-acetyltransferase OatWY from Neisseria meningitidis","volume":"284","author":"Lee","year":"2009","journal-title":"J. Biol. Chem."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1021\/acschembio.6b00928","article-title":"A Chemical Biology Solution to Problems with Studying Biologically Important but Unstable 9-O-Acetyl Sialic Acids","volume":"12","author":"Khedri","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.chembiol.2014.01.002","article-title":"Chemical Biology Approaches to Designing Defined Carbohydrate Vaccines","volume":"21","author":"Anish","year":"2014","journal-title":"Chem. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1021\/acs.accounts.7b00043","article-title":"The Glycan Microarray Story from Construction to Applications","volume":"50","author":"Hyun","year":"2017","journal-title":"Acc. Chem. Res."},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Moginger, U., Resemann, A., Martin, C.E., Parameswarappa, S., Govindan, S., Wamhoff, E.C., Broecker, F., Suckau, D., Pereira, C. L., and Anish, C. (2016). Cross Reactive Material 197 glycoconjugate vaccines contain privileged conjugation sites. Sci. Rep., 6.","DOI":"10.1038\/srep20488"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1002\/jms.3258","article-title":"Mapping the glycation sites in the neoglycoconjugate from hexasaccharide antigen of Vibrio cholerae, serotype Ogawa and the recombinant tetanus toxin C-fragment carrier","volume":"48","author":"Jahouh","year":"2013","journal-title":"J. Mass Spectrom."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jchromb.2017.04.009","article-title":"The combined use of analytical tools for exploring tetanus toxin and tetanus toxoid structures","volume":"1054","author":"Bayart","year":"2017","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1016\/j.vaccine.2013.04.036","article-title":"Emergence of serogroup X meningococcal disease in Africa: Need for a vaccine","volume":"31","author":"Xie","year":"2013","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/1\/12\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:56:21Z","timestamp":1760194581000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/6\/1\/12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,25]]},"references-count":91,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,3]]}},"alternative-id":["vaccines6010012"],"URL":"https:\/\/doi.org\/10.3390\/vaccines6010012","relation":{"has-preprint":[{"id-type":"doi","id":"10.20944\/preprints201801.0291.v1","asserted-by":"object"}]},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,25]]}}}